AU2008100233A4 - Oral anaesthetic gel - Google Patents

Oral anaesthetic gel Download PDF

Info

Publication number
AU2008100233A4
AU2008100233A4 AU2008100233A AU2008100233A AU2008100233A4 AU 2008100233 A4 AU2008100233 A4 AU 2008100233A4 AU 2008100233 A AU2008100233 A AU 2008100233A AU 2008100233 A AU2008100233 A AU 2008100233A AU 2008100233 A4 AU2008100233 A4 AU 2008100233A4
Authority
AU
Australia
Prior art keywords
gel
anaesthetic
oral
lignocaine
flavouring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008100233A
Other versions
AU2008100233B4 (en
Inventor
Mark Feldschuh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ORAL BIOSCIENCE Pty Ltd
Original Assignee
ORAL BIOSCIENCE Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2004313612A external-priority patent/AU2004313612A1/en
Application filed by ORAL BIOSCIENCE Pty Ltd filed Critical ORAL BIOSCIENCE Pty Ltd
Priority to AU2008100233A priority Critical patent/AU2008100233B4/en
Publication of AU2008100233A4 publication Critical patent/AU2008100233A4/en
Application granted granted Critical
Publication of AU2008100233B4 publication Critical patent/AU2008100233B4/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Landscapes

  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Description

13-03-08;15:36 ;A TatlocK Associates IP AUST Canberra ;61 3 9864 9900 7/ 16 00 o 1
O
SORAL ANAESTHETIC GEL n Area of the Invention O This invention relates to the area of topical anaesthesia or desensitisation. In 00 particular it relates to a topical anaesthetic which is adapted to be used on C mucous membranes and can be usefully applied in the field of dentistry despite having other applications.
Background to the Invention Local anaesthetics have been used in creams and ointments for many years.
Usually however there is a problem with the penetration of the drug or chemical due to the physio-chemical properties of both the drug and the base in which it is used.
In addition one of the products used topically on non mucous membranes is a cream and is not suitable for use on mucous membranes such as in the mouth.
Another product which can be used orally is a paste that has been formulated for the mouth but unfortunately does not adhere to the gum or mouth particularly well when used for dental purposes.
COMS ID No: ARCS-182858 Received by IP Australia: Time 16:39 Date 2008-03-13 13-03-08;15:36 ;A Tatlock Associates IP AUST Canberra ;61 3 9664 9900 8/ 16 00 o 2 0 N It has been suggested that a gel base could be used to adhere in the mouth i however to date none exist which are able to provide the anaesthetic effect en required and additionally are quite unpalatable and therefore unsuitable for oral anaesthetic use.
Cci Outline of the Invention 00 It is an object of this invention to provide a topical anaesthetic for use on mucosal o surfaces which does not exhibit the problems outlined above. It is a further object of the invention to provide such a topical anaestheticwhich is sufficiently palatable that it can readily be used for dental purposes.
The invention is an oral anaesthetic gel including an anaesthetic in a transdermal gel base having added flavouring with a bitterness suppressant.
It is preferred that the gel base used be Pluronic Lecithin Organogel (PLO or Pluronic Gel) and that its viscosity be adjusted as required by the addition of suitable thickeners. It is further preferred that PLO strengths range from 2% to It is further preferred that the active agent or ingredient otherwise referred to as the active pharmaceutical ingredient (API) be lignocaine base US P or alternatively the HCL salt. It is also preferred that other active ingredients may be tetracaine benzocaine, amethocaine or prilocaine as salts.
COMS ID No: ARCS-182858 Received by IP Australia: Time 16:39 Date 2008-03-13 13-03-08:15:36 ;A Tatlock Associates IR AUST Canberra ;61 3 9664 9900 9/ 16 00 3
O
CI In order that the invention may be more readily understood we shall describe by Sway of non limiting example a particular embodiment of the invention.
Examples of Embodiments of the Invention 8 A first preferred application of the invention is in the area of dentistry and will be 00 described here.
This embodiment of the invention is a gel formulation that is very quickly absorbed into the mucosa. As absorption is rapid the dentist can inject anaesthetic into a patient's gum with a major reduction in pain in the injection site in as little as seconds or up to 2 minutes.
Trauma is further reduced psychologically by the presence of palatable flavouring in the gel which masks the customary bitter taste of the analgesic material used as the anaesthetic.
Examples of the invention to be described here are PLO gel formulations having Lignocaine and being flavoured.
Dental Anaesthetic Gel A preferred formulation for a dental anaesthetic gel is as follows: Lignocaine USP 10.0g Sodium Metabisulphite 0.1g COMS ID No: ARCS-182858 Received by IP Australia: Time 16:39 Date 2008-03-13 13-03-08;15:36 ;A Tatlock Associates IP AUST Canberra ;61 3 9554 9GOO 10/ 16 00 o4 0 CN Ethoxydiglycol Reageant Lecithin Isopropyl Palmitate/Myristate Solution 22ml eC Flavouring 12ml en Saccharin Sodium 0.20g O Stevia powder extract 1g 00 Simethicone 0.02ml o Pluronic Gel 20% up to 100ml.
The procedure for making the formulation is as follows: Calibrate a beaker to final volume Weigh the powder ingredients Add Lignocaine, Saccharine, Sodium Metabisulphate to the beaker with flavouring and ethoxy diglycol reagent.
Add a magnetic stirring bar and stir mixture well Create a vortex with the stir bar and slowly add the stevia to avoid lumps.
Add lecithin isopropyl myristate solution and allow lignocaine to dissolve remove stirring bar and add Pluronic gel 20% to volume pour mixture into an appropriately sized unguatorjar, remove excess Close lid tightly with mixing blade in place, expel all air and mix for a few minutes COMS ID No: ARCS-182858 Received by IP Australia: Time 16:39 Date 2008-03-13 13-03--0;15:36 ;A Tatlock Assocates IP AUST Canbe-ra ;61 3 9864 9900 11/ 16 00 CIf desired the gel may be stored in a syringe with any excess air removed or Sotherwise stored as desired. The air removal is preferably achieved by turning the csyringe upside down and allowing the gel to settle on the plunger before removing the air.
O The compounding procedure is an important part of the process as force used in 00 mixing can encourage micelle formation. It is therefore preferred that this be reduced by using syringe to syringe techniques, a Dremel tool with mixing blade, electric mortars and ointment mills which can aid in the process.
Teething Gel A preferred formulation for a teething gel is as follows: Lignocaine USP Chlorhexadine Acetate 5% Solution 0.7ml Phenylepherine HCL USP 0.25g Sodium Metabisulphate 0.1g Ethoxy Diglycol Reagent Lecithin Isopropyl Palmitate/Myristate Solution 22ml Flavouring 12ml Pluronic Gel 20% up to 100ml.
The procedure for making the formulation is as follows: COMS ID No: ARCS-182858 Received by IP Australia: Time 16:39 Date 2008-03-13 13-03-08;15:36 ;A Tatlock Associates IP AUST Canberra ;61 3 9664 9900 #12/ 16 00 O 6 0 C Weigh the Lignocaine, Phenylepherine HCI, Sodium Metabisulphate i and add to an appropriately calibrated beaker.
n Measue the Ethoxy Diglycol Reagent, and Lecithin Isopropyl Palmitate Solution, Chlorhexidine solution and add to the beaker en with a magnetic stirring bar.
O place beaker on a stirring plate and stir until the ingredients are 00 mixed o- whilst stirring add flavouring, sweetener, bitterness suppressant and colour if necessary remove stirring bar and add Pluronic gel 20% to volume pour mixture into an appropriately sized unguatorjar, remove excess Close lid tightly with mixing blade in place, expel all air and mix for a few minutes If desired the gel may be stored in a syringe with any excess air removed or otherwise stored as desired. The air removal is preferably achieved by turning the syringe upside down and allowing the gel to settle on the plunger before removing the air.
The compounding procedure is an important part of the process as force used in mixing can encourage micelle formation. It is therefore preferred that this be reduced by using syringe to syringe techniques, a Dremel tool with mixing blade, electric mortars and ointment mills which can aid in the process.
COMS ID No: ARCS-182858 Received by IP Australia: Time 16:39 Date 2008-03-13 13--03-08;15:35 ;A Tatlock Associates P AUST Canberra ;61 3 9664 9900 13/ 18 00 7 c While a variety of flavours may be used they may include the following: SPINA COLADA per 100ml Bitterness Suppressant 2.5ml, Pineapple 3ml, Pina Colada 2.5ml, Peach Oil Coconut 1 ml, yellow 0.2ml O CARAMEL per 100 ml 00 Bitterness Suppressant 2.5ml, Cinnamon Oil 1ml, Caramel 8ml STRAWBERRY per 100 ml Bitterness suppressant 2.5ml, Strawberry 4ml, Blackberry Oil 1ml, watermelon Krisgel to thicken, red 0.1ml ORANGE per 100 ml Bitterness suppressant 2.5ml, Orange cream 3.5ml, Orange natural concentrate Tangerine oil 1ml, red 0.1ml, yellow 0.1ml BUBBLEGUM per 100 ml drp sweet, 50 drp bitter, 70drp bubble, 60drp banana, 40 drp grape TROPICAL FLAVOUR per 100ml drp sweet, 50 drp bitter, 80 drp strawberry, 20 drp peach oil, 10 drppineapple, dro pina colada, 10 drp coconut, 10 drp banana COMS ID No: ARCS-182858 Received by IP Australia: Time 16:39 Date 2008-03-13 13-03-08;15:36 ;A Tatlock Associates IP AUST Canberra ;61 3 9664 9900 14/ 16 00 o 8 Ci WILD BERRY per 100ml drp sweet, 50 drp bitter, 80 drp strawberry, 20 drp blackberry oil, 40 drp cn watermelon and 2% Krisgel to thicken.
en The above are examples of the gel formulation of the invention and it is envisaged o that actual concentrations of ingredients can vary as can the actual ingredients 00 which are chosen depending on the specific application.
0 For example the strength of the analgesic used in the gel for dentistry could be typically up to 10% lignocaine as described above while for over the counter type medications such as the teething gel 1% or 2% could be used.
In addition the previously suggested anaesthetic agents can generally be used up to 10% to achieve a specified effect while benzocaine can be up to As has also been suggested the viscosity of any batch of the gel formulation can be adjusted by adding an appropriate thickener.
Clearly the concept of can be achieved in a variety of ways and while particular embodiments of the invention have been described herein it is to be understood that variations and modifications in the features described can still lie within the scope of the invention.
COMS ID No: ARCS-182858 Received by IP Australia: Time 16:39 Date 2008-03-13

Claims (1)

13-03-08:15:38 ;A TatlocK Associates IP AUST Canberra ;61 3 9664 9900 1/ 00 O 9 C The claims defining the invention are as follows: 1. An oral anaesthetic gel including an anaesthetic in a transdermal gel base m having added flavouring with a bitterness suppressant. en 2. An oral anaesthetic gel as claimed in claim 1 wherein the base is Pluronic o Gel in the range of 10% to 00 o 3. An oral anaesthetic gel as claimed in any one of claims 1 to 3 wherein the anaesthetic is Lignocaine in the range 1% to 4. An oral anaesthetic gel as claimed in claim 3 for use as a teething gel including Lignocaine USP 1 to 3g, Chlorhexidine Acetate 5% solution 0.3 ml to 1.0ml, Phenylephrine HCL USP 0.1g to 0.5gm, Sodium Metabisulphite 0.01gmto 0.2gm, Ethoxyl Diglycol Reagent 5ml, to 15ml Lecithin Isopropyl Palmate/Myristrate Solution, Flavouring 5ml to 20ml, Pluronic Gel 10% to to 100ml. An oral anaesthetic gel as claimed in claim 4 for use in dentistry including Lignocaine USP 5mg to 15mg, Sodium Metabisulphite 0.01gm to 0.2gm, Ethoxy Diglycol Reagent 5ml to 15ml, Lecithin Isopropyl Palmitate/Myristrate solution 15ml to 30ml, flavouring 5 to 20ml, Saccharin Sodium 0.1gm to 0.3gm, Stevia powder extract 0.1gm to 0.4gm, Simethicone 0.01 to0.05ml, and Pluronic Gel 10% to COMS ID No: ARCS-182858 Received by IP Australia: Time 16:39 Date 2008-03-13
AU2008100233A 2004-01-15 2008-03-13 Oral anaesthetic gel Ceased AU2008100233B4 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2008100233A AU2008100233B4 (en) 2004-01-15 2008-03-13 Oral anaesthetic gel

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2004900176 2004-01-15
AU2004313612A AU2004313612A1 (en) 2004-01-15 2004-12-22 Oral anaesthetic gel
AU2008100233A AU2008100233B4 (en) 2004-01-15 2008-03-13 Oral anaesthetic gel

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
AU2004313612A Division AU2004313612A1 (en) 2004-01-15 2004-12-22 Oral anaesthetic gel

Publications (2)

Publication Number Publication Date
AU2008100233A4 true AU2008100233A4 (en) 2008-04-17
AU2008100233B4 AU2008100233B4 (en) 2008-11-20

Family

ID=39338474

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008100233A Ceased AU2008100233B4 (en) 2004-01-15 2008-03-13 Oral anaesthetic gel

Country Status (1)

Country Link
AU (1) AU2008100233B4 (en)

Also Published As

Publication number Publication date
AU2008100233B4 (en) 2008-11-20

Similar Documents

Publication Publication Date Title
JP2000505093A (en) Tasteful aqueous liquid compositions for bitter agents
EP1909798A2 (en) Oral suspension of prednisolone acetate
JP2012505172A (en) Liquid pharmaceutical formulation with paracetamol
BR112021008197A2 (en) edaravone suspension for oral administration
WO2016028968A1 (en) Natural suspending agent including a synergistic blend of xanthan gum and konjac powder for oral pharmaceutical suspensions
TW200808374A (en) Sugar-free storage-stable antihistaminic syrups
US9326935B2 (en) Atomoxetine solution
JP2012515154A (en) Formulation for oral mucosal administration of analgesic molecule and / or antispasmodic molecule
MX2010011701A (en) Liquid formulation for deferiprone with palatable taste.
US20070110689A1 (en) Oral anaesthetic gel
EP1143973A2 (en) Compositions having improved stability
EP1146876A2 (en) Compositions having improved stability
AU2008100233A4 (en) Oral anaesthetic gel
CN111773203A (en) Preparation process of phenylephrine hydrochloride-containing composition
EP3669879A1 (en) Pharmaceutical composition in the form of an oral suspension including a flavonoid fraction comprising diosmin, and xanthan gum
ES2209490T3 (en) ORAL SERTRALINE CONCENTRATE.
AU2004313612A1 (en) Oral anaesthetic gel
JP2008531556A (en) Aqueous liquid pharmaceutical composition stable at room temperature
AU2011203572A1 (en) Oral anaesthetic gel
US11617795B2 (en) Pharmaceutical syrup formulation or suspension
US20220387363A1 (en) Pharmaceutical liquid composition, kit of parts comprising the pharmaceutical liquid composition, and method for preparing the pharmaceutical liquid composition
NL2024160B1 (en) Pharmaceutical liquid composition, kit of parts comprising the pharmaceutical liquid composition, and method for preparing the pharmaceutical liquid composition
JPH05194232A (en) Orally administering liquid agent of trimethoprim
WO2023203124A1 (en) New formulation of atropine
GB2617419A (en) Stable composition of chloral hydrate

Legal Events

Date Code Title Description
FGI Letters patent sealed or granted (innovation patent)
FF Certified innovation patent
MK22 Patent ceased section 143a(d), or expired - non payment of renewal fee or expiry